Adaxion Therapeutics
2 known investors
ADAXION develops deimmunized biologic therapies using its ADAx platform, which incorporates proprietary CD22 ligands to eliminate therapeutic-specific B cells and reduce anti-drug antibody responses. The company focuses on enabling biotherapeutics that would otherwise face prohibitive immunogenicity.
BiotechDeep Tech
Investors · 2
Frequently asked questions
- What does Adaxion Therapeutics do?
- ADAXION develops deimmunized biologic therapies using its ADAx platform, which incorporates proprietary CD22 ligands to eliminate therapeutic-specific B cells and reduce anti-drug antibody responses. The company focuses on enabling biotherapeutics that would otherwise face prohibitive immunogenicity.
- Who are Adaxion Therapeutics's investors?
- Adaxion Therapeutics's investors include JDRF T1D Fund, Vivo Capital.